David Sallman – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Mon, 22 Apr 2024 12:45:24 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png David Sallman – VJRegenMed https://mirror.vjregenmed.com 32 32 The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01 https://mirror.vjregenmed.com/video/qyspydxsu08-the-safety-and-efficacy-of-ucart123v1-2-in-rr-aml-results-from-ameli-01/ Thu, 26 Jan 2023 12:11:29 +0000 https://mirror.vjregenmed.com/video/qyspydxsu08-the-safety-and-efficacy-of-ucart123v1-2-in-rr-aml-results-from-ameli-01/ David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of the AMELI-01 Phase I trial of UCART123v1.2 in adult patients with relapsed refractory (R/R) CD123+ acute myeloid leukemia (AML; NCT04106076). UCART123v1.2 is an anti-CD123 allogeneic CAR-T product, that has been genetically modified to minimize the occurrence of graft-versus-host disease (GvHD). Overall, results suggest UCART123v1.2 is well tolerated, though severe cytokine release syndrome (CRS) did occur, and that three-drug lymphodepletion optimizes CAR-T expansion and patient responses. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML https://mirror.vjregenmed.com/video/gqsnw1bxpi0-results-from-a-phase-i-trial-of-rapidly-manufactured-prgn-3006-ultracar-t-in-rr-aml/ Thu, 26 Jan 2023 12:11:28 +0000 https://mirror.vjregenmed.com/video/gqsnw1bxpi0-results-from-a-phase-i-trial-of-rapidly-manufactured-prgn-3006-ultracar-t-in-rr-aml/ In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines the completed Phase I results for Prgn-3006 Ultracar-T in patients with relapsed/refractory (R/R) CD33+ acute myeloid leukemia (AML). Prgn-3006 Ultracar-T is an autologous CAR-T cell product with decentralized manufacturing that significantly reduces the time between apheresis and CAR-T infusion compared to standard autologous CAR-T therapies. Overall, results suggest that Prgn-3006 Ultracar-T is well tolerated, with only a few grade 3 cytokine release syndrome (CRS) events and no dose-limiting toxicities. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>